As companies outsource drug and device development overseas, reducing development time and research and development costs, additional legal concerns are raised. Last month a...
I just noticed that in late 2011, the HHS-OIG modified some of the boilerplate in its advisory opinions. The boilerplate is very objectionable, probably...